Clinical trials: Non-Alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD.
- Trial name
- NCT04944992
- Testing
- Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
- Where
- 69 sites in United States, Argentina and 14 more
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Inflammation, Fatty Liver Disease
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.
- Trial name
- NCT06802731
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
NAFLD, Inflammatory Bowel Diseases
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol.
- Conditions
- NAFLD, Inflammatory Bowel Diseases, Steatosis, Fibrosis, Liver
- Trial name
- PONI (NCT06814600)
- Testing
- Transient elastometry
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Non-alcoholic Fatty-liver Disease
Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis
Primary Objectives: 1. To determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2.
- Trial name
- Sweet Bev (NCT01188083)
- Testing
- Fructose Drink, Glucose Drink
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emory University
Overweight, Microtia
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
Previous work of the investigators demonstrated the anti-obesity and anti-steatosis potential of the Amazonian fruit camu-camu (CC) in a mouse model of diet-induced obesity [1].
- Conditions
- Overweight, Microtia, Endotoxemia, Metabolic Syndrome
- Trial name
- NCT04130321
- Testing
- Camu camu
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laval University
Nonalcoholic Steatohepatitis (NASH)
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT04521114)
- Testing
- leronlimab 700 mg, leronlimab 350 mg
- Where
- 7 sites in United States
- Volunteers
- 87 people
- Sponsor
- CytoDyn, Inc.
Nonalcoholic Fatty Liver Disease
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in…
- Trial name
- NCT03998514
- Testing
- CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- CohBar, Inc.
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Liver Fibrosis, Liver Cirrhosis
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC
- Trial name
- NCT07716384
- Testing
- Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan)
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
NAFLD, ACS - Acute Coronary Syndrome
Prevalence of NAFLD in ACS Patients
Addressing CVD risk in patients with NAFLD is the aspect of the disease most amenable to medical management and so improving long-term clinical outcomes.
- Trial name
- PADAC (NCT05378321)
- Testing
- Non-invasive diagnostic testing
- Where
- Belgium
- Volunteers
- 225 people
- Sponsor
- Ziekenhuis Oost-Limburg
Non-alcoholic Fatty Liver Disease NAFLD
Hepatic Mitochondrial Metabolism in Fatty Liver Disease in Humans
The goal of this clinical trial is to investigate in healthy volunteers the mechanisms by which ethanol and lipids, the two key risk factors of steatotic liver disease (SLD), affect liver mitochondrial metabolism.
- Trial name
- ALPHA (NCT06559878)
- Testing
- 13C-α-Ketoisocaproic Acid Breath Test, Ethanol, Lipid Emulsion
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Non-Alcoholic Fatty Liver Disease
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
In developed counties Non-alcoholic fatty liver disease (NAFLD) becomes the most common cause of chronic liver disease , but its prevalence in developing countries like India is also increasing (10 -20%).Till date, there is no…
- Trial name
- NCT04475276
- Testing
- Alphalipoic acid
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Insulin Resistance, Prediabetic State
Pancreatic Clamp in NAFLD
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp…
- Conditions
- Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05724134
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Columbia University
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Arthritis, Rheumatoid
Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory systemic disease. It has a worldwide distribution and can affect all age group. The peak incidence is between fourth and sixth decade.
- Trial name
- NCT00394238
- Testing
- Ultrasonographic imaging
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Shaare Zedek Medical Center
NAFLD, Web
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
The web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with NAFLD, always tracking their performance status, enabling them to grasp the knowledge of healthy weight…
- Conditions
- NAFLD, Web, Childhood Obesity
- Trial name
- NCT05527938
- Testing
- web-based intervention
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shaoxing Maternity and Child Health Care Hospital
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens
Nonalcoholic Steatohepatitis
Norursodeoxycholic Acid vs. Placebo in NASH
This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral…
- Trial name
- NCT05083390
- Testing
- norUrsodeoxycholic acid
- Where
- Austria
- Volunteers
- 363 people
- Sponsor
- Dr. Falk Pharma GmbH
Non-Alcoholic Fatty Liver Disease
Histological Improvement of NASH With Prebiotic
This trial will investigate the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH. In a single-blind, placebo controlled, randomized pilot trial will be conduced in individuals with liver…
- Trial name
- NCT03184376
- Testing
- Prebiotic oligofructose
- Volunteers
- 14 people
- Sponsor
- University of Calgary
Nonalcoholic Steatohepatitis, Fatty Liver Disease
Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease
Trial Synopsis: Bovine Colostrum for patients with non alcoholic fatty liver disease (NAFLD). Design: This is a single-arm, open-label, before-and after exploratory trial of 30 days of Bovine Colostrum Powder (BCP) to improve…
- Trial name
- NCT01016418
- Testing
- Bovine colostrum powder
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.